BACKGROUND: The incidence of penile cancer in Europe lies in the range of 0.9 to 2.1 cases per 100 000 persons per year. Carcinogenesis is associated with human papilloma virus (HPV) infection and with chronic inflammation. METHODS: This review is based on publications (2010-2017) retrieved by a selective search in PubMed and EMBASE and on the guidelines of the European Association of Urology, the European Society of Medical Oncology, the National Comprehensive Cancer Network, and the National Institute for Health and Care Excellence (NICE). RESULTS: 95% of cases of penile cancer are accounted for by squamous cell carcinoma, whose numerous subtypes have different clinical courses. Chronic preputial inflammation due to phimosis or lichen sclerosus is often associated with penile cancer. Circumcision lowers the risk of penile cancer (hazard ratio: 0.33). Maximally organ-preserving surgery with safety margins of no more than a few millimeters is the current therapeutic standard, because a local recurrence, if it arises, can still be treated locally with curative intent. Local radiotherapy can be performed in early stages. Lymphogenic metastasis must be treated with radical lymphadenectomy and adjuvant chemotherapy. Patients with clinically unremarkable inguinal lymph nodes nonetheless need invasive lymph node staging because of the high rate of lymphogenic micrometastasis. CONCLUSION: Penile cancer is curable in all early stages with the appropriate treatment, but its prognosis depends crucially on the proper management of the regional (i.e., inguinal) lymph nodes. In many countries, the treatment of this rare disease entity has been centralized.
BACKGROUND: The incidence of penile cancer in Europe lies in the range of 0.9 to 2.1 cases per 100 000 persons per year. Carcinogenesis is associated with human papilloma virus (HPV) infection and with chronic inflammation. METHODS: This review is based on publications (2010-2017) retrieved by a selective search in PubMed and EMBASE and on the guidelines of the European Association of Urology, the European Society of Medical Oncology, the National Comprehensive Cancer Network, and the National Institute for Health and Care Excellence (NICE). RESULTS: 95% of cases of penile cancer are accounted for by squamous cell carcinoma, whose numerous subtypes have different clinical courses. Chronic preputial inflammation due to phimosis or lichen sclerosus is often associated with penile cancer. Circumcision lowers the risk of penile cancer (hazard ratio: 0.33). Maximally organ-preserving surgery with safety margins of no more than a few millimeters is the current therapeutic standard, because a local recurrence, if it arises, can still be treated locally with curative intent. Local radiotherapy can be performed in early stages. Lymphogenic metastasis must be treated with radical lymphadenectomy and adjuvant chemotherapy. Patients with clinically unremarkable inguinal lymph nodes nonetheless need invasive lymph node staging because of the high rate of lymphogenic micrometastasis. CONCLUSION:Penile cancer is curable in all early stages with the appropriate treatment, but its prognosis depends crucially on the proper management of the regional (i.e., inguinal) lymph nodes. In many countries, the treatment of this rare disease entity has been centralized.
Authors: Kyrollis Attalla; David J Paulucci; Kyle Blum; Harry Anastos; Kelvin A Moses; Ketan K Badani; Philippe E Spiess; John P Sfakianos Journal: Urol Oncol Date: 2017-10-12 Impact factor: 3.498
Authors: Nicola Nicolai; Laura Maria Sangalli; Andrea Necchi; Patrizia Giannatempo; Anna Maria Paganoni; Maurizio Colecchia; Luigi Piva; Mario Achille Catanzaro; Davide Biasoni; Silvia Stagni; Tullio Torelli; Daniele Raggi; Elena Faré; Giorgio Pizzocaro; Roberto Salvioni Journal: Clin Genitourin Cancer Date: 2015-08-06 Impact factor: 2.872
Authors: Kekeli Kodjo Adanu; Bernard Toboh; Evans Akpakli; Mary Monney; Isaac Asiedu; Maxwell Nyinah; Bright Wereh; Yaw Amoah; Matthew Kyei; James Edward Mensah Journal: Pan Afr Med J Date: 2022-01-13
Authors: Xinxi Deng; Yang Liu; Xiangpeng Zhan; Tao Chen; Ming Jiang; Xinhao Jiang; Luyao Chen; Bin Fu Journal: Front Oncol Date: 2022-06-17 Impact factor: 5.738
Authors: Ahmet Murat Aydin; Jad Chahoud; Jacob J Adashek; Mounsif Azizi; Anthony Magliocco; Jeffrey S Ross; Andrea Necchi; Philippe E Spiess Journal: Nat Rev Urol Date: 2020-08-18 Impact factor: 14.432